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Neuronal identityThe neuroendocrine hypothalamus regulates a spectrum of essential biological processes and underlies a
range of diseases from growth failure to obesity. While the exploration of hypothalamic function has
progressed well, knowledge of hypothalamic development is poor. In particular, very little is known about the
processes underlying the genesis and speciﬁcation of the neurons in the arcuate and ventromedial nuclei.
Recent studies demonstrate that the proneural basic helix-loop-helix transcription factor Mash1 is required
for neurogenesis and neuronal subtype speciﬁcation in the ventral hypothalamus. We demonstrate here that
Ngn3, another basic helix-loop-helix transcription factor, is expressed in mitotic progenitors in the arcuate
and ventromedial hypothalamic regions of mouse embryos from embryonic days 9.5–17.5. Genetic fate
mapping and loss of function studies in mice demonstrate that Ngn3+ progenitors contribute to subsets of
POMC, NPY, TH and SF1 neurons and is required for the speciﬁcation of these neuronal subtypes in the ventral
hypothalamus. Interestingly, while Ngn3 promotes the development of arcuate POMC and ventromedial SF1
neurons, it inhibits the development of NPY and TH neurons in the arcuate nuclei. Given the opposing roles of
POMC and NPY neurons in regulating food intake, these results indicate that Ngn3 plays a central role in the
generation of neuronal populations controlling energy homeostasis in mice.n, NW7 4LL, UK.
tes and Metabolism, Harvard
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The mammalian hypothalamus is involved in regulating multiple
physiological functions, which include growth and development,
immune system activity, thermoregulation, food intake, ﬂuid homeo-
stasis, sleep regulation, as well as reproductive and maternal
behaviours (Krononberg et al., 2007; Michaud, 2001). The rodent
hypothalamus has a complex structure composed of multiple nuclei
corresponding to dense groups of neuronal cell bodies. These neurons
project axons to numerous regions of the CNS in addition to producing
neuropeptide hormones (Swanson and Sawchenko, 1983). One group
of neuroendocrine neurons, located in the arcuate nucleus (ARC) and
ventromedial region (VMH) of the hypothalamus, do not release
neuropeptides into the general circulation, but rather respond to
peripheral hormones in order to regulate energy balance. In brief,
energy related signals such as leptin are integrated by responsive ﬁrst
order neurons such as the anorexic pro-opoiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and
orexic neuropeptide Y (NPY)/Agouti-related peptide (AgRP) neurons,
and relayed to second order melanocrotin-4 receptor (MC4R)
expressing neurons in the PVN and the lateral hypothalamic area.
The opposing effects of POMC and NPY neurons results in a negative
feedback loop that maintains energy balance within physiological
parameters (reviewed in Barsh and Schwartz, 2002; `Broberger, 2005;
Morton et al., 2006; Srinivas et al., 2001). In addition to the POMC and
NPY neurons of the ARC, steriodiogenic factor 1 (SF1) expressing
neurons of the VMH are central regulators of energy balance in
response to leptin and deletion of leptin receptor in SF1-expressing
neurons results in increase body weight and susceptibility to diet-
induced obesity in mice (Dhillon et al., 2006).
Neurogenin1 (Ngn1), Ngn2 and Ngn3 are basic-helix-loop-helix
(bHLH) proteins, which together deﬁne a novel subfamily of atonal-
related genes (Gradwohl et al., 1996; Ma et al., 1996; Sommer et al.,
1996). All three genes are expressed in the hypothalamus in both
zebraﬁsh (Wang et al., 2001) andmice (McNay et al., 2006; Ravassard et
al., 1997; Sommer et al., 1996). Ngn1 and Ngn2 function as proneural
genes in the cranial sensory ganglia and spinal cord and thus promote
both neurogenesis and notch-delta mediated lateral inhibition
(reviewed inBertrand et al., 2002). Ngn2 also regulate neuronal subtype
Fig. 1. Ngn3 mRNA and protein expression pattern in the ventral hypothalamus. (A–F') Coronal sections of mouse embryos. Ngn3 transcripts and protein are similarly expressed in
the lateral margins of the ventricular zone surrounding the third ventricle of the VMH and ARC in the hypothalamus from E9.5 to E17.5. Scale bar corresponds to 100 μm.
Abbreviations: OS, optic stalk.
Fig. 2.Ngn3 is expressed in ventral hypothalamic progenitors. (A–F) Coronal sections of
mouse embryos. (Inserts a–d) Higher magniﬁcation of the boxed region in A–D with
nuclei counterstained with DAPI (blue). (A–D) Double immunoﬂuorescent staining
reveals that Ngn3 is co-expressed with mitotic markers, such as Ki67 (arrows in A, B
and inserts a and b) and Mash1 (arrows in C, D and inserts c and d) at E10.5 and E13.5.
(E, F) Ngn3 is not co-expressed with POMC in postmitotic ARC neurons at E10.5 (E) or
E13.5 (F). The neural tissue is outlined by dotted lines in A and C–F. Scale bar
corresponds to 75 μm. Abbreviations: 3v, third ventricle.
407M. Pelling et al. / Developmental Biology 349 (2011) 406–416identity in the cerebral cortex, acting to promote glutaminergic cell fate
(Fode et al., 2000).
Loss and gain of function studies of Ngn3 in mice suggest that Ngn3
acts as a genetic switch that speciﬁes an endocrine cell fate in pluripotent
pancreatic progenitors (Apelqvist et al., 1999; Grapin-Botton et al., 2001;
Schwitzgebel et al., 2000); however, nothing is known about its role in
neuronal lineages. Ngn3 is also required for endocrine cell fate
speciﬁcation in multipotent intestinal progenitor cells (Jenny et al.,
2002; Lee et al., 2002). We therefore determined whether Ngn3 might
have similar roles in regulating neurogenesis and neuronal subtype
speciﬁcation in the hypothalamus. Firstly, we demonstrate that Ngn3 is
expressed in mitotic progenitors in the ARC/VMH regions of the
hypothalamus. Secondly, genetic fate mapping studies provided evi-
dence that Ngn3 progenitors contribute to subsets of arcuate TH, POMC,
NPYneurons and ventromedial SF1neurons. Thirdly, analysis ofNgn3−/−
mice demonstrates that Ngn3 is required for proper development of all
these neuronal subtypes. Interestingly, while Ngn3 promotes the
development of arcuate POMC and ventromedial SF1 neurons, it inhibits
the development of NPY and TH neurons in the arcuate nuclei. Since
POMC and NPY have opposing regulatory functions in regulating food
intake, the differential requirements for Ngn3 in the development of
these neurons suggests that Ngn3 likely plays a critical role in regulating
energy homeostasis in mammals.
Materials and methods
Generation and genotyping of mutant embryos and animals
Ngn3+/− mice, and Ngn3Cre mice were generated and genotyped
as previously described (Gradwohl et al., 2000; Schonhoff et al., 2004).
The Ngn3 mutant animals were kept as heterozygous stocks and
intercrossed to obtain Ngn3−/−mutants at different embryonic stages.
The Ngn3Cre heterozygous mice were crossed with R26RYFP/YFP reporter
mice (Srinivas et al., 2001) andwere kept as double heterozygousmice.
Male Ngn3Cre/+;R26RYFP/+ animals were crossed with R26RYFP/YFP
females to obtain Ngn3Cre/+;R26RYFP/+ or Ngn3Cre/+;R26RYFP/YFP
embryos (referred to henceforth as Ngn3;R26RYFP embryos) for the
genetic fate mapping studies. At all times, animals were handled
according to the Society of Neuroscience Policy on the Use of Animals in
Neuroscience Research, as well as the European Communities Council
Directive.
Immunohistochemistry and in situ hybridisation of brain sections
Embryos or dissected embryonic headswereﬁxed for 30min (E10.5–
E13.5), 1 h (E15.5), andovernight (E17.5) at 4 °C in4%paraformaldehydein PBS and cryoprotectedwith30% sucrose in PBS, then embedded inOCT
compound (VWR International, Poole, UK). The blocks were then
cryosectioned on a cryostat at 10 μm for E10.5, 12 μm for E13.5 and
E15.5, and 14 μm for E17.5 (CM3050S; Leica, Nussloch, Germany).
Fig. 3. Co-localization of Ngn3 and YFP in Ngn3Cre;R26RYfp embryos (A–C) and demonstration that Ngn3+ progenitors contribute to POMC, SF1, TH and NPY neurons in the ventral
hypothalamus (D–L). (A–L) Coronal sections of mouse embryos. (A–C) Co-expression of YFP and Ngn3 in ventral hypothalamic cells (arrow) and postmitotic neurons (arrowhead) of
Ngn3Cre/+;R26RYFP embryos. (D–L) Double immunoﬂuorescent (arrow heads) staining showing co-expression of YFP with POMC (D–F), YFP with SF1 (G–I), YFP with TH (J, K) and
YFP with NPY (L) in postmitotic neurons of the ventral hypothalamus in Ngn3Cre/+;R26RYFP embryos at various stages. Insets e, f, h–l show higher magniﬁcation of boxed region in
the corresponding panels. Arrowheads point to double-labelled cells in these insets. The third ventricle (3v) is outlined by dotted lines. Scale bar corresponds to 100 μm (A–D, G),
150 μm (E, F, H–L) or 15 μm (e, f, h–l).
408 M. Pelling et al. / Developmental Biology 349 (2011) 406–416Section in situ hybridisations was performed as previously described
(Vernay et al., 2005). The following antisense RNA probes have been
used: Mash1 (Guillemot and Joyner, 1993), POMC (Good et al., 1997),
Ngn3 (Gradwohl et al., 2000), Npy (Higuchi et al., 1988), Nhlh2 (Good et
al., 1997), NeuroD (Lee et al., 1995), Scg10 (Stein et al., 1988), Dll1
(Bettenhausen et al., 1995) and Hes5 (Casarosa et al., 1999).For immunohistochemistry, sections were incubated overnight at
4 °C with the appropriate primary antibody diluted in 0.1% TritonX100
and 1% BSA in PBS. Sections were then extensively washed in PBS and
incubated for 2 h at room temperature with a secondary antibody
conjugated with a ﬂuorochrome. For double antibody labelling
experiment, sections were washed and then incubated for 2 h at room
Fig. 4. Notch-mediated lateral inhibition, neurogenesis, proliferation and cell death are not affected in the Ngn3 null mutants. (A–P) Coronal sections of mouse embryos. (A–F) No
change in expression of Scg10 (A, B, I and J)Dll1 (C, D, K and L) andHes5 (E, F, M and N) expression in the ventral hypothalamuswas detected by in situ hybridization analyses of wild-
type andNgn3−/− embryos at E10.5 and E13.5. The neural tissue is outlined by dotted lines. (G, H) Immunohistochemistry analysis also showed normalMash1 expression inNgn3−/−
embryos at E10.5, while expression of Mash1 transcripts is not affected in Ngn3−/− embryos at E13.5 (O, P). Scale bar corresponds to 100 μm.
409M. Pelling et al. / Developmental Biology 349 (2011) 406–416temperature in the second primary antibody diluted in 0.1% triton and
1% BSA in PBS, followed by washing and incubation in another
secondary antibody conjugated with another ﬂuorochrome for 2 h at
room temperature. Sections were then extensively washed and
mounted in DAPI-containing vectashield H-1005 (Vector Laboratories,
Burlingame, CA).
The following primary antibodies were used: rabbit anti-TH
(AB152, 1:100; Chemicon, Temecula, CA), sheep anti-TH (AB1542,
1:100; Chemicon, Temecula, CA), rabbit anti-SF1 (1:1000; Hatano et
al., 1994, kind gift of K. Morohashi), mouse anti-ACTH (CR1096M,
1:300; Cortex Biochem Inc.), sheep anti-γMSH (1:100; kind gift of A.
Bicknell), rabbit anti-GFP (1:500; Molecular Probes), sheep anti-GFP
(1:400;Molecular Probes), mouse anti-Mash1 (1:200; Developmental
Studies Hybridoma Bank (DSHB), IA, USA), rat anti-Ki67 (1:50,
DAKO), rabbit anti-Ngn3 (1:2000, generous gift of M. German), rabbit
anti-NPY (1:100, T-4070, Peninsula Laboratories, CA, USA) and mouse
anti-caspase-3 active (1:1000, R&D systems). The following second-
ary antibodies were used: rabbit anti-Cy3 (1:200; Jackson ImmunoR-
esearch Laboratories) , sheep anti-Cy3 (1:200; Jackson
ImmunoResearch Laboratories), rat anti-Cy3 (1:200; Jackson Immu-
noResearch Laboratories), rabbit anti-Alexa 488 (1:500; Molecular
Probes), mouse anti-Alexa 594 (1:500; Molecular Probes), and mouse
anti-Alexa 488 (1:500; Molecular Probes).Image analysis and cell counting
Bright ﬁeld images were obtainedwith a Zeiss LSM510microscope
and Axiovision 2.1 software, while confocal images were obtained
with a Leica TCS SP2 confocal microscope. Images were processed
using Adobe Photoshop CS (Adobe Systems, San Jose, CA).
All cell counts were carried out using the Cell Counter plug-in for
ImageJ (http://rsbweb.nih.gov/ij/). Cell counts were derived from an
average of three counts of cell nuclei from a single series of cryostat
cut sections per animal, with a mean taken from a minimum of three
series per expression pattern of interest. Except where stated, all
positive cells were counted across the whole A-P axis of the
expression domain of each series, and as a result cells were counted
from between four and seven sections of each series. For reasons of
expediency, only the left or right domain of expressionwas counted in
each series, and the total multiplied by 2 to estimate the number of
positive cells across the whole series. NPY and αMSH immunostained
cells were only counted within the ARC, the boundary of which was
determined by use of an anatomical atlas of the developing mouse
brain and the authors' own judgment based on experience. In order to
estimate if there is any change in the total number of ARC cells in the
hypothalamus of Ngn3−/− mutant embryos, ﬂuorescent immunohis-
tochemical labelling for SF1 protein expression alongwith DAPI nuclei
Fig. 5. Reduced numbers of POMC neurons in Ngn3−/− embryos throughout embryonic
development. (A–H) Coronal sections of mouse embryos. Immunoﬂuorescent staining
(A, B) and in situ hybridization analyses (C–H) revealed severe reduction in the
numbers of POMC neurons in Ngn3−/− compared to wild-type embryos from E10.5 to
E17.5. (I–L). Pomc is also expressed in the pituitary at E15.5 and E17.5.
Table 1
Numerical data of the cell counts of ARC and VMH neuronal populations in Ngn3−/−
mutant compared to wild-type embryos.
Mean number of positive cells per series (n=3)
WT Ngn3−/−
Mean SD Mean SD
E10.5 Pomc 103.75 6.24 20.75 14.86
SF1 207.33 19.09 52.67 17.67
Nhlh2 2769 357.53 302.52 198.43
E13.5 Pomc 562.39 146.74 115.28 74.32
SF1 3695.11 545.42 2438.67 50.36
TH 897.06 41.43 911.67 29.04
Nhlh2 218.31 43.40 21.18 8.63
E15.5 Pomc 736.25 196.56 309.79 94.79
Npy 351 16.52 755.67 147.41
SF1 8551.46 733.23 5772.79 626.82
TH 985.47 197.79 1477.47 259.29
Nhlh2 3608 491.23 428.5 206.87
E17.5 Pomc 858.50 154.65 326.13 65.87
Npy 747.33 58.73 1548 247.78
SF1 10099.33 1408.77 7448.67 933.50
TH 813.67 45.54 1189 76.31
Nhlh2 3726 832.16 746.67 189.01
Data represent mean of total number of positive cells per series across the entire
detectable expression domain of each population marker (n=3 for each genotype).
410 M. Pelling et al. / Developmental Biology 349 (2011) 406–416staining was carried out at E17.5 and images obtained at one z-level
for two representative sections of each series obtained. In each section
Adobe Photoshop CS was used to highlight a region of interest from
the most ventral boundary of SF1 expression, the boundary of the
third ventricle and the ventral most boundary of the hypothalamus.
The outline of this region was then exported as a new layer and
applied to the image of DAPI stained cell nuclei from the same stack,
and the positive staining counted, excluding those cells bisected by
50% or more by the bounding line. Co-expression with αMSH was
carried out to determine whether a substantial proportion of POMC
neurons would be excluded from this count at this stage of
development. In all cases, t-tests were then carried out to assess for
any signiﬁcant difference in immuno-positive or dig-labelled in situ
stained cells between wild-type and mutant animals.
Results
Ngn3 is expressed in a subset of progenitors and early postmitotic
neurons in the ARC and VMH
Neurogenin 3 (Ngn3) transcripts are ﬁrst detected in the
ventricular zone of the ventral hypothalamus at E9.5 (Fig. 1A). This
expression pattern expands from E10.5 onwards (Fig. 1B) with higher
numbers of Ngn3+ cells in the ARC/VMH region of the hypothalamus
at E12.5 (Fig. 1C) and E13.5 (Fig. 1D). Subsequently, the number of
Ngn3+ cells decrease, with only a few cells expressing Ngn3mRNA in
these regions at E17.5 (Fig. 1E and F). This dynamic change in Ngn3
expression pattern during development was conﬁrmed by analyses of
the expression of Ngn3 protein by immunohistochemistry with a
Ngn3-speciﬁc antibody (Fig. 1A'–F'), except that there was a delay in
the onset of detectable expression of Ngn3 protein, which was not
detectable at E9.5.
Since Ngn3 expression occurred in cells near or in the ventricular
zone of the hypothalamus, we next determined whether Ngn3 was
expressed in mitotic or postmitotic cells using double antibody
labelling experiments. Some Ngn3+ cells also expressed Ki67, a
marker for mitotic cells, at E10.5 and E13.5 (arrows in Fig. 2A and B,
respectively). Ngn3 is also co-expressed with Mash1 (arrows in
Fig. 2C, D), which labels only progenitor cells, in the hypothalamus
(McNay et al., 2006). Furthermore, double-labelled Ngn3+ POMC
cells were not detected indicating that Ngn3 is not expressed in
postmitotic POMC ARC neurons. Altogether, these results indicate
Ngn3 is expressed in progenitors in the ARC/VMH region of the
hypothalamus. These results also suggest that Ngn3 is initiated
slightly later and likely acts downstream of Mash1 in these
progenitors. Consistent with this interpretation, Ngn3 expression is
lost in Mash1−/− mutants at E10.5 but is recovered at E13.5 (McNay
et al., 2006).
Ngn3+ progenitors contribute to subsets of ARC and VMH neuronal
populations
We obtained direct evidence that Ngn3+ progenitors give rise to
distinct neuronal subtypes in the ARC/VMH region by performing
genetic fate mapping studies using a Ngn3-Cre BAC transgenic line
that allowed us to permanently label any cell expressing Ngn3 and its
progeny (Schonhoff et al., 2004). This Cre line faithfully mimics Ngn3
expression in the small intestine and pancreas. Double-labelling of
YFP and Ngn3 by immunohistochemistry identiﬁed YFP+Ngn3+
cells in the ventricular andmantle zone (Fig. 3C), indicating that YFP is
expressed in Ngn3-expressing progenitors and postmitotic neurons in
the hypothalamus of Ngn3;R26RYFP embryos. However, some Ngn3+,
YFP- cells were also observed in more dorsal hypothalamic regions,
suggesting that there is a delay in Cre and consequently YFP
expression, compared to the timing of Ngn3 expression (Fig. 3A–C).
This delay in the activation of reporter genes driven off Ngn3
Fig. 6. Comparison of the total number of DAPI stained cell nuclei in wild-type and Ngn3−/− embryos at E17.5. (A) Expression of αMSH and SF1 determined by ﬂuorescent
immunohistochemical and DAPI staining. (B) Arcuate domain approximated by area ventral to SF1 expression domain boundary. (C) DAPI staining in the arcuate domain deﬁned by
SF1 expression. (D) No overall difference in total number of DAPI positive cells is observed in Ngn3−/− mutants compared to WT littermates (n=3).
Fig. 7. Two bHLH genes, Nhlh2 and NeuroD, are downstream targets of Ngn3. (A–F)
Coronal sections of mouse embryos. In situ hybridization of tissue sections of WT and
Ngn3−/− mutant littermates. Expression of Nhlh2 is severely reduced in Ngn3−/−
mutant compared to wild-type embryos at E10.5 (A and B), and E17.5 (C and D). The
neural tissue is outlined by dotted lines in A and B. NeuroD expression is also missing in
Ngn3−/− mutants (F), while it is expressed in nascent neurons in the ventral
hypothalamus at E13.5 (E). Scale bar corresponds to 100 μm.
411M. Pelling et al. / Developmental Biology 349 (2011) 406–416promoter regulatory sequences has already been reported (Jenny et
al., 2002). We ﬁrst examined whether Ngn3+ progenitors generated
POMC neurons in the ARC by double labelling with YFP and POMC
antibodies in Ngn3;R26RYFP embryos. Quantitative analysis showed
that the percentage of YFP+/POMC neurons over the total number of
POMC neurons was 96% at E10.5 and reduced to 67% at E15.5 (Fig. 3D–
F and data not shown). These results indicate that a subset of POMC
neurons are derived from Ngn3+ progenitors in Ngn3;R26RYFP
embryos and suggests that later born POMC neurons may be derived
from Ngn3- progenitors.
We also investigated whether other neuronal populations in the
ARC/VMH region are derived from Ngn3 progenitors. We analysed
only populations where antibodies are available to perform double
antibody labelling experiments with YFP. Our results demonstrate
that a subset of TH dopaminergic (Fig. 3J and K), and NPY neurons in
the ARC (Fig. 3L) and SF1 neurons in the ARC and VMH (Fig. 3G, H, I)
are also derived from Ngn3+ progenitors. The contribution to POMC,
TH and SF1 neurons at E13.5 has been conﬁrmed using E13.5
heterozygous embryos from Ngn3EYFP knock-add-on (Mellitzer et al.,
2004; Supplementary Fig. 1) and Ngn3LacZ ((Jenny et al., 2002, data
not shown) mouse lines, although the contribution to the different
neuronal subtypes is lower in the hypothalamus of these embryos
(data not shown) as was expected since Ngn3EYP/+ and Ngn3LacZ/+
embryos mark Ngn3+ cells in a transient manner, while there is
permanent labelling of Ngn3+ cells in Ngn3Cre/+ embryos.
Ngn3 is not required for the generation of neurons in the ARC/VMH
region
Since other Ngn genes, such as Ngn1 and Ngn2, have a proneural
function in the CNS, we investigated whether Ngn3 is required for
neurogenesis in the ventral hypothalamus. Neuronal differentiation,
determined by the expression of an overt neuronal marker SCG10,
Fig. 8. Increase in the numbers of TH and NPY neurons in Ngn3−/−mutants from E15.5 onwards. (A–H) Coronal sections of mouse embryos. An increase in the number of TH and NPY
neurons was detected by immunohistochemisty inNgn3−/−mutants compared with wild-type embryos at E15.5 (A, B and E, F) and E17.5 (C, D and G, H). Similarly, an increase in the
numbers of NPY neurons was observed by in situ hybridization at E15.5 (I, J) and E17.5 (K, L). Dotted lines delineate region of ARC used for the purpose of cell counting. Scale bar
corresponds to 100 μm.
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B, I and J). Furthermore, expression of downstream targets of
proneural genes involved in lateral inhibition, such as Dll1 and Hes5,
were also unaffected in Ngn3mutant compared to wild-type embryos
(Fig. 4C, D, K and L). Consistent with these results, we also found that
proliferation and apoptosis, measured by the expression of Ki67 and
phosphorylated caspase 3, were not affected in the hypothalamus of
Ngn3 mutant embryos at both these stages (Supplementary Fig. 2).
The absence of a phenotype in neurogenesis suggests that Ngn3 does
not have a proneural function or it functions redundantly withMash1,
which is still normally expressed in ARC/VMH progenitors in Ngn3
mutant embryos at E10.5 and E13.5 (Fig. 4G, H, O and P), to regulate
neurogenesis.
Ngn3 is required for the development of a subset of POMC neurons
POMC is one of the earliest markers of ARC neurons and is
expressed from E10.5 onwards (McNay et al., 2006). Within the ARC it
is processed into αMSH, which inhibits appetite, and therefore is the
main anorexigenic neuropeptide of the hypothalamus. Since some
POMC neurons are derived from Ngn3+ progenitors, we determined
the status of these neurons by immunohistochemisty with a γMSH-
speciﬁc antibody at E10.5 or by ISH to detect POMC transcripts from
E13.5 onwards. Quantitative analyses revealed that 80% of POMCneurons are lost in Ngn3 mutants compared to wild-type embryos at
E10.5 and E13.5 (Figs. 5A–D and 10, Table 1). Subsequently, there is a
recovery in the number of POMC neurons with only 60% of POMC
neurons missing at E15.5 (Figs. 5E, F and 10, Table 1). The reduction in
POMC neuronal cell number persisted at E17.5 (Figs. 5G, H and 10),
which was the latest stage analyzed since Ngn3 mutant animals die
early postnatally (Gradwohl et al., 2000). However, any reduction in
POMC cells at this stage was not matched by a reduction in the total
number of cell bodies in the ARC (Fig. 6).
Expression of bHLH transcription factors, Nhlh2 and NeuroD are affected
in the ARC
Nhlh2 (nescient helix-loop-helix 2) is a bHLH transcription factor,
which is expressed in the rostral ARC POMC neurons. Nhlh2 knockout
mice develop adult-onset obesity (Coyle et al., 2002; Good et al.,
1997) and Nhlh2 is required for the normal expression of the key
processing enzyme, pro-hormone convertase 1 (PC1) (Jing et al.,
2004). PC1 has been shown to proteolytically cleave the POMC
precursor in a tissue-speciﬁc manner to produce mature POMC
products, including α-Melanocyte Stimulating Hormone (α-MSH)
(Nillni, 2007). In addition, Nhlh2 expression is reduced in the cortex
of Ngn2 null mutants (Schuurmans et al., 2004) and conversely forced
expression of Ngn2 induced Nhlh2 in the ventral telencephalonwithin
Fig. 9. SF1 neurons are also reduced in number in Ngn3−/− compared to wild-type
embryos. (A–H) Coronal sections of mouse embryos. Immunohistochemistry analyses
indicate that the number of SF1 neurons in the ARC and VMH at E10.5 (A, B) and in the
VMH is reduced from E13.5 to E17.5 (C–H). Scale bar corresponds to 100 μm.
413M. Pelling et al. / Developmental Biology 349 (2011) 406–41624 h (Mattar et al., 2008), indicating thatNhlh2 is a downstream target
gene of Ngn2. We therefore examined whether Ngn3 could have a
similar role in regulating Nhlh2 expression in the ventral hypothal-
amus. A dramatic reduction in the number ofNhlh2 cells was observed
inNgn3mutants from E10.5 to E17.5 (Figs. 7A–D and 10). Quantitative
analyses showed that 20% Nhlh2+ cells remained in the ARC at E17.5
(Table 1).
NeuroD, another bHLH transcription factor, has also been shown to
be regulated by neurogenin genes in the nervous system (Fode et al.,
2000; Ma et al., 1996) and by Ngn3 in the pancreas (Huang et al.,
2000). Consistent with these results, NeuroD expression is also
missing in Ngn3 embryos (Fig. 7E, F). Hence, the expression of several
bHLH genes expressed in postmitotic neurons in the ARC appears to
be dependent on Ngn3.
Expansion of TH and NPY ARC populations in the Ngn3 mutants
Since Ngn3+progenitors also generate TH and NPY neurons in the
ARC, we determined the status of these neurons in Ngn3−/− embryos.
TH is the ﬁrst rate-limiting enzyme for the synthesis of dopamine fromtyrosine. Dopamine produced in the A12 (Ben-Jonathan and Hnasko,
2001) ARC neurons is required for providing inhibitory control of
prolactin secretion. Quantitative analyses of the number of THneurons
revealed no change in the number of A12 dopaminergic neurons
betweenWT andmutant embryos at E13.5 (Fig. 10, Table 1). However,
therewas a 50% increase in number of THneurons inNgn3−/−mutants
both at E15.5 and E17.5 (Figs. 8A–D and 10, Table 1).
NPY is a neuropeptide belonging to the pancreatic polypeptide
family and is one of the major orexigenic peptide expressed in the
ARC. Expression of NPY causes an increase in food intake and body
weight, leading to obesity. NPY neurons are detected from E15.5
onwards in the ARC (Fig. 8E). There is a dramatic increase in the
number of NPY neurons in Ngn3−/− mutant embryos compared to
control littermates at both E15.5 and E17.5, with a doubling in size of
the population (Figs. 8E–H and 10, Table 1). Altogether, these results
demonstrate that loss of Ngn3 results in changes in the ratio of
neuronal subtypes in the ARC. While the numbers of POMC neurons
are reduced, the numbers of NPY and TH neurons are increased in the
ventral hypothalamus.
Given the role of Ngn3 in regulating endocrine cell fate in the
pancreas, we also determined whether Ngn3 is also required for the
development of GHRH neuroendocrine cells in the ARC. Expression of
Ghrh appears unchanged in the ARC of Ngn3 mutant embryos
(Supplementary Fig. 3E, F). Accordingly, expressions of transcription
factors Hmx2 (Wang et al., 2004) and Gsh2 (Mutsuga et al., 2001)
which regulate the expression of GHRH in the ARC are also not
affected in the absence of Ngn3 at E13.5 (Supplementary Fig. 3A–D).
These results therefore indicate that Ngn3 speciﬁcally regulates the
development of A12 TH neuroendocrine cells.
The SF1 population, a marker of the VMH, is also reduced in the Ngn3
mutants
SF1 is an orphan nuclear receptor that is expressed in the gonad,
adrenal cortex, pituitary and brain (Ikeda et al., 1994). In the brain its
expression is limited to the VMH of the hypothalamus. SF1 knockut
mice lack a histologically distinct VMH and exhibit late onset obesity
(Dellovade et al., 2000; Ikeda et al., 1995). SF1 speciﬁcally marks VMH
at E13.5, but also labels POMC neurons in the ARC at E10.5 (McNay et
al., 2006). We used SF1 as a marker to determine the status of the
VMH during development. A signiﬁcant reduction of SF1 neurons in
the VMHwas observed at E13.5, E15.5 and E17.5, and in both the ARC
and VMH neurons at E10.5 in Ngn3mutant embryos (Fig. 10, Table 1).
Quantitative analysis showed that the reduction in the number of SF1
neurons was approximately 30% from E13.5 onwards (Figs. 9 and 10,
Table 1). In contrast, there was no obvious difference in the numbers
of Nkx2.2+ neurons in the VMH (Supplementary Fig. 4). These results
indicate that Ngn3 is also required speciﬁcally for the development of
SF1 but not for the expression of Nkx2.2+ neurons in the VMH.
Discussion
Cascade of bHLH genes regulate the development of POMC neurons
Ngn3 is not required for neurogenesis of the ventral hypothalamus.
This conclusion is based on the fact that there are no apparent changes
in cell proliferation, cell death, and neuronal cell number in the ARC
and VMH in Ngn3−/− embryos during development. In addition,
expression of downstream targets of proneural bHLH genes, involved
in Notch-mediated lateral inhibition, such as Dll1 and Hes5, was not
modiﬁed in Ngn3 mutant embryos. On the other hand, Mash1 has
previously been shown to have a proneural function and to act
upstream of Ngn3 to regulate neurogenesis in the ventral hypothal-
amus (McNay et al., 2006). Loss of Mash1 leads to a loss of Ngn3
transcripts in ARC progenitors between E10.5 and E13.5. Contrary to
this, normal expression of Mash1 was observed in the hypothalamus
Fig. 10. Graphical representation of the changes in ARC and VMH neuronal populations in Ngn3 mutant compared to wild-type embryos. Quantiﬁcation of the number of distinct
neuronal populations in Ngn3−/−mutants compared to wild-type embryos. There is a reduction in the percentage of POMC and SF1 neurons in Ngn3−/−mutants, when compared to
WT embryos at all four developmental stages analyzed, although a signiﬁcant recovery in the percentage of POMC neurons is seen at later developmental stages. In contrast, there is
an increase in the percentage of TH and NPY neurons at E15.5 and E17.5, but not at E13.5.
414 M. Pelling et al. / Developmental Biology 349 (2011) 406–416of Ngn3−/− mutants at E10.5. Mash1 may be compensating for Ngn3
function as a proneural gene. To address this possibility, we generated
double Mash1;Ngn3 double mutants, but failed to recover any double
homozygous embryos at E10.5 and E12.5 from 20 litters ofMash1+/−;
Ngn3+/− intercrosses. The reason for their embryonic lethality
remains to be determined, but this early defect precludes the
possibility of using double Mash1;Ngn3 double mutants for deter-
mining whether Ngn3 has a proneural function during neurogenesis.
Ngn3, however, is required for the expression of two other bHLH
factors NeuroD and Nhlh2 that are expressed in nascent neurons
outside the ventricular zone. Interestingly, NeuroD has previously
been shown to be a direct target of Ngn3 in the developing pancreas
and to function downstream to maintain the differentiation program
initiated by Ngn3 (Huang et al., 2000). In other parts of the CNS, Ngn1
and Ngn2 also acts upstream of NeuroD to promote the differentiation
of neurons in the olfactory epithelium and cerebral cortex respec-
tively (Cau et al., 2002; Fode et al., 2000) Ngn2 also induces NeuroD
and Nhlh2 expression in the ventral telencephalon (Mattar et al.,Fig. 11. Model of bHLH transcription factors regulating POMC expression at the transcriptio
αMSH peptide levels by regulating the expression of Nhlh2. Whether NeuroD is also involv2008). Hence, the regulatory interactions between Neurogenins and
NeuroD and Neurogenins and Nhlh2 are conserved in the hypothal-
amus. The function of NeuroD in the hypothalamus has not been
described, while loss of Nhlh2 leads to adult-onset obesity that is in
part contributed by post-translation control of the processing of the
POMC propolypeptide by the PC1 convertase (Jing et al., 2004). Taken
together, these studies suggest a model whereby a cascade of bHLH
genes is involved in the regulation of POMC expression at the
transcriptional and postranscriptional level at sequential steps in the
lineage (Fig. 11).
Ngn3 is a critical determinant of subsets of ARC and VMH neurons
Our genetic fate mapping studies using Ngn3-Cre mice demon-
strate that some but not all arcuate POMC, NPY, TH neurons and
ventromedial SF1 neurons arise from Ngn3+ progenitors. These
results, conﬁrmed in fate mapping studies with two other strains of
mice, Ngn3LacZ and Ngn3EYFP, raise the possibility that subpopulationsnal and postranscriptional level. Ngn3 regulates the expression of Pomc and likely also
ed in the regulation of Pomc remains to be determined.
415M. Pelling et al. / Developmental Biology 349 (2011) 406–416of POMC, NPY, TH and SF1 neurons are generated from progenitors
that do not express Ngn3 and hence are not labelled in these Ngn3Cre;
R26RYFP embryos. Alternatively, since there is a temporal delay in
activation of reporter compared to the timing of Ngn3 transcription,
Cre, LacZ and YFPmay only label a subset of descendants from Ngn3–/–
populations. Consistent with the former hypothesis, loss of Ngn3 leads
to a severe but partial reduction of POMC neurons in mouse embryos
during development. The numbers of POMC neurons lost in Ngn3
mutant embryos correlate well with the numbers of POMC neurons
derived from Ngn3+ progenitors in the fate mapping studies at E15.5.
Reduction in POMC+neuronal number is not due to a general effect
on neurogenesis, which occurs normally in Ngn3−/− embryos.
Consequently, the most parsimonious explanation of these results is
that Ngn3 is required for the development of a subset of POMC
neurons, perhaps in a cell intrinsic manner.
Remarkably, loss of Ngn3 has an opposite effect on NPY and TH
neurons, leading to increase in the number of these neurons in Ngn3
mutant embryos. These results indicate that Ngn3 represses NPY and
TH fate. Since Ngn3+ progenitors give rise to all three types of
neurons, Ngn3 may act within a common progenitor for all three
lineages, and positively select POMC fate at the expense of NPY and
TH. Alternatively, distinct Ngn3+ progenitors generate unipotent
POMC, NPY and TH neurons and loss of POMC neurons leads to
compensatory changes in the number of other neuronal subtypes. The
latter possibility is less likely given that there are no changes in the
absolute number of ARC neurons at E17.5 and there is no obvious
change in cell proliferation in the ARC of Ngn3−/− embryos at E10.5
and E13.5. Independent of the mechanism, our results clearly
demonstrate that Ngn3 has different effects on regulating the number
of POMC versus NPY and TH neurons. It is also noteworthy that while
TH neuroendocrine cells are affected, there was no obvious change in
the number of GHRH neuroendocrine cells. Therefore, Ngn3 is
required for the development of some but not all neuroendocrine
cells in the ventral hypothalamus.Conclusion
In this paper, we have focused primarily on the role of Ngn3 in
regulating the development of NPY and POMC neurons, which
contribute to the regulation of food intake and energy balance in
mammals. Importantly, our studies demonstrate that Ngn3 has
opposite roles in regulating the development of POMC and NPY
neurons. These results suggest that Ngn3 activity plays an important
role in regulating the numbers of POMC and NPY neurons in the
hypothalamus during development and consequently may play a role
in diseases, such as obesity and Type II diabetes. Finally, it is
noteworthy that besides the interplay of neuronal and hormonal
mechanisms regulating energy homeostasis between the hypothala-
mus and the pancreas and between the hypothalamus and the
gastrointestinal tract, a common molecular determinant Ngn3
governs the differentiation of endocrine cell types in all three organs.Acknowledgments
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